You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Launched by both national labs and regional and specialty firms, the offerings provide testing as well as guidance on how to best structure testing programs.
The FDA has added an at-home self-collection template to its SARS-CoV-2 EUA guidance as more firms seek to develop sampling kits for use in homes.
High-profile groups have proposed population-scale testing as key to a safe reopening, but the test numbers they propose dwarf current and projected lab capacity.
Driven by increased demand for SARS-CoV-2 assays and a return of routine testing, the rise suggests that the industry could be moving toward a recovery.
A number of labs have said that not only are they able to fulfill all current PCR test requests, but that they are operating at below capacity for these tests.
Replacing nasopharyngeal swabs with saliva samples or nasal swabs could increase throughput and convenience, as well as relieve reagent and equipment shortages.
Overall revenues were $2.82 billion, up from $2.79 billion in Q1 2019, but organic revenues were down 2 percent due largely to the COVID-19 pandemic.
A number of labs and informatics firms are using test data to help guide the response to the virus in a spirit similar to that of initiatives like Lab 2.0.
The EUA allows patients to collect samples using LabCorp's Pixel by LabCorp COVID-19 Test home collection kit and will be available in coming weeks.
With clinical labs suffering large drops in volumes as patients stay away from draw centers, remote sampling could provide a way to offer routine testing.